Publications by authors named "D Daoussis"
Background: There is considerable practice variation in labelling, diagnosis and treatment of adults with sterile bone inflammation. We developed a expert consensus recommendations on the disease definition, diagnosis and treatment of this rare condition.
Methods: Systematic literature review and Grading of Recommendations, Assessment, Development and Evaluations-based appraisal of evidence, two Delphi surveys and three digital and in-person consensus meetings with a multidisciplinary expert panel and patient representatives.
Objective: To present the characteristics of patients with potential difficult-to-treat (D2T) PsA.
Methods: We used data from the Greek multicentre registry of PsA patients. D2T PsA was defined as follows: patients with at least 6 months' disease duration, who have failed to at least one conventional synthetic DMARD and at least two biologic DMARDs/targeted synthetic DMARDs with a different mechanism of action and have either at least moderate disease activity (MODA) defined as DAPSA (Disease Activity index in PSoriatic Arthritis) >14, and/or are not at minimal disease activity (MDA).
Background: Psoriatic arthritis (PsA) is a heterogenous chronic inflammatory disease affecting skin, joints, entheses, and spine with various extra-musculoskeletal manifestations and comorbidities. The reported patient, disease and treatment characteristics in the modern therapeutic era are limited.
Methods: In this cross-sectional, multi-centre, nationwide study, we recorded the demographic, clinical, and therapeutic characteristics as well as the comorbidities of patients with PsA seen for 1 year (1/1/2022-31/12/2022).
Is there a Role for Anti-IL-5 Therapies in Eosinophilic Fasciitis?
Mediterr J Rheumatol
December 2023
Article Synopsis
- Eosinophilic Fasciitis (EF) is a rare disease characterized by swelling in the subcutaneous fascia and muscle, primarily affecting the upper arms and thighs, with no standard treatment available.
- A review of studies focused on anti-Interleukin-5 (IL-5) therapies found only one case where reslizumab, an anti-IL-5 therapy, successfully treated a patient whose symptoms were not controlled by standard immunosuppressive treatments.
- The exact cause of EF is still unknown, and while traditional treatments like corticosteroids are often ineffective and have side effects, targeting eosinophils with IL-5 therapies may offer a promising alternative approach.
Article Synopsis
- * A study using databases like MEDLINE and Cochrane assessed how often PP occurs in AS patients on different TNFi medications, finding it happens in 0.5-1% of cases with a latency of 2-11 months.
- * Certolizumab was the safest TNFi regarding PP, while infliximab was the most associated with it; PP typically improves after stopping the medication, but further research is needed.